A novel drug delivery system: Insulin free needle injection technology

2^nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

November 23-24, 2012 Hyderabad International Convention Centre, India

Sanjay Reddy Akula and Jyothi Edla

Accepted Abstracts: Pharmaceut Reg Affairs

Abstract :

Diabetes mellitus is chronic, progressive systemic disease characterized by dysfunction insulin function. Physiological resistance to self injection or needle phobia has been seen across many populations in treatment of diabetes and require injectable products two or three times a day. A series of discoveries led to the development of the hypodermic needle which underwent significant changes. To overcome the problems related to needle based injections in treatment of diabetes there is one technology NFIT (Needle freed injectable technology).Needle free delivery is done conveniently both for solids and liquids. Various needle free injectors are available in the market like Biojector, vitajet, iject, cool.click etc. These formulations are designed for better acceptability and patient convenience. They offer less pain and no needle phobia. They are ideally suited to chronic injections of varying doses of insulin, proteins and monoclonal antibodies. And other novel drug formulations for diabetic patients i.e. insulin micro pump, insulin transdermal patches, insulin nanopump, insulin pen, insulin tablets, insulin capsules, insulin spray, inhalable insulin.